miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response

Oncotarget

Volumn 7, Issue 1, 2016, Pages 786-797

  Cataldo, Alessandra ^a,b   Cheung, Douglas G ^a   Balsari, Andrea ^b,c   Tagliabue, Elda ^c   Coppola, Vincenzo ^a   Iorio, Marilena V ^c   Palmieri, Dario ^a   Croce, Carlo M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

ATM; Breast cancer; Cisplatin; DDR; E2F1; miR 302b

Indexed keywords

ATM PROTEIN; CISPLATIN; MICRORNA; MICRORNA 302B; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; ATM PROTEIN, HUMAN; CASPASE 3; CASPASE 7; E2F1 PROTEIN, HUMAN; MIRN302 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE RESPONSE; DNA END JOINING REPAIR; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MDA-MB-231 CELL LINE; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; 3' UNTRANSLATED REGION; BREAST TUMOR; CELL CYCLE; CELL SURVIVAL; DNA DAMAGE; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; GENETICS; HELA CELL LINE; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BREAST NEOPLASMS; CASPASE 3; CASPASE 7; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DNA DAMAGE; E2F1 TRANSCRIPTION FACTOR; FEMALE; FLOW CYTOMETRY; HELA CELLS; HUMANS; MICRORNAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 85016414945     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6381     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61:69-90.
2. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Annals of oncology. 2012; 23 Suppl 6:vi7-12.
3. Crown J, O'Shaughnessy J and Gullo G. Emerging targeted therapies in triple-negative breast cancer. Annals of oncology. 2012; 23 Suppl 6:vi56-65.
4. Roy V, Pockaj BA, Allred JB, Apsey H, Northfelt DW, Nikcevich D, Mattar B and Perez EA. A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338. American journal of clinical oncology. 2013; 36:540-544.
5. Mayer IA, Abramson VG, Lehmann BD and Pietenpol JA. New strategies for triple-negative breast cancer- deciphering the heterogeneity. Clinical cancer research. 2014; 20:782-790.
6. Kelland LR. Preclinical perspectives on platinum resistance. Drugs. 2000; 59 Suppl 4:1-8; discussion 37-38.
7. Filipowicz W, Bhattacharyya SN and Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature reviews Genetics. 2008; 9:102-114.
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136:215-233.
9. Iorio MV and Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO molecular medicine. 2012; 4:143-159.
10. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nature reviews Cancer. 2012; 12:613-626.
11. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R and Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008; 455:58-63.
12. Wu S, Huang S, Ding J, Zhao Y, Liang L, Liu T, Zhan R and He X. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene. 2010; 29:2302-2308.
13. Allen KE and Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Molecular cancer therapeutics. 2010; 9:3126- 3136.
14. Hu H and Gatti RA. MicroRNAs: new players in the DNA damage response. Journal of molecular cell biology. 2011; 3:151-158.
15. Landau DA and Slack FJ. MicroRNAs in mutagenesis, genomic instability, and DNA repair. Seminars in oncology. 2011; 38:743-751.
16. Ren J, Jin P, Wang E, Marincola FM and Stroncek DF. MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. Journal of translational medicine. 2009; 7:20.
17. Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha KY, Chung HM, Yoon HS, Moon SY, Kim VN and Kim KS. Human embryonic stem cells express a unique set of microRNAs. Developmental biology. 2004; 270:488-498.
18. Wang L, Yao J, Zhang X, Guo B, Le X, Cubberly M, Li Z, Nan K, Song T and Huang C. miRNA-302b suppresses human hepatocellular carcinoma by targeting AKT2. Molecular cancer research. 2014; 12:190-202.
19. Wang L, Yao J, Shi X, Hu L, Li Z, Song T and Huang C. MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC cancer. 2013; 13:448.
20. Chen PH, Shih CM, Chang WC, Cheng CH, Lin CW, Ho KH, Su PC and Chen KC. MicroRNA-302b-inhibited E2F3 transcription factor is related to all trans retinoic acidinduced glioma cell apoptosis. Journal of neurochemistry. 2014; 131:731-742.
21. Zhang M, Yang Q, Zhang L, Zhou S, Ye W, Yao Q, Li Z, Huang C, Wen Q and Wang J. miR-302b is a potential molecular marker of esophageal squamous cell carcinoma and functions as a tumor suppressor by targeting ErbB4. Journal of experimental & clinical cancer research. 2014; 33:10.
22. Zhu R, Yang Y, Tian Y, Bai J, Zhang X, Li X, Peng Z, He Y, Chen L, Pan Q, Fang D, Chen W, Qian C, Bian X and Wang R. Ascl2 knockdown results in tumor growth arrest by miRNA-302b-related inhibition of colon cancer progenitor cells. PloS one. 2012; 7:e32170.
23. Khalili M, Sadeghizadeh M, Ghorbanian K, Malekzadeh R, Vasei M and Mowla SJ. Down-regulation of miR-302b, an ESC-specific microRNA, in Gastric Adenocarcinoma. Cell journal. 2012; 13:251-258.
24. Tabrizi M, Khalili M, Vasei M, Nouraei N, Mansour Samaei N, Khavanin A, Khajehei M and Mowla SJ. Evaluating the miR-302b and miR-145 expression in formalin-fixed paraffin-embedded samples of esophageal squamous cell carcinoma. Archives of Iranian medicine. 2015; 18:173- 178.
25. Ge T, Yin M, Yang M, Liu T and Lou G. MicroRNA-302b suppresses human epithelial ovarian cancer cell growth by targeting RUNX1. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2014; 34:2209-2220.
26. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, Yao G, Medina A, O'Brien-Jenkins A, Katsaros D, Hatzigeorgiou A, Gimotty PA, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:9136-9141.
27. Chen D and Yang H. Integrated analysis of differentially expressed genes in breast cancer pathogenesis. Oncology letters. 2015; 9:2560-2566.
28. Liang Z, Ahn J, Guo D, Votaw JR and Shim H. MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharmaceutical research. 2013; 30:1008-1016.
29. De Cecco L, Berardi M, Sommariva M, Cataldo A, Canevari S, Mezzanzanica D, Iorio MV, Tagliabue E and Balsari A. Increased sensitivity to chemotherapy induced by CpGODN treatment is mediated by microRNA modulation. PloS one. 2013; 8:e58849.
30. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA and Dynlacht BD. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes & development. 2002; 16:245-256.
31. Blattner C, Sparks A and Lane D. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Molecular and cellular biology. 1999; 19:3704-3713.
32. O'Connor DJ and Lu X. Stress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb. Oncogene. 2000; 19:2369-2376.
33. Lin WC, Lin FT and Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATMdependent phosphorylation. Genes & development. 2001; 15:1833-1844.
34. Shiloh Y and Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013; 14:197-210.
35. McKinnon PJ. ATM and the molecular pathogenesis of ataxia telangiectasia. Annual review of pathology. 2012; 7:303-321.
36. Berkovich E and Ginsberg D. ATM is a target for positive regulation by E2F-1. Oncogene. 2003; 22:161-167.
37. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nature reviews Molecular cell biology. 2008; 9:759-769.
38. O'Driscoll M and Jeggo PA. The role of double-strand break repair-insights from human genetics. Nature reviews Genetics. 2006; 7:45-54.
39. Ransburgh DJ, Chiba N, Ishioka C, Toland AE and Parvin JD. Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination. Cancer research. 2010; 70:988-995.
40. Yu H, Pak H, Hammond-Martel I, Ghram M, Rodrigue A, Daou S, Barbour H, Corbeil L, Hebert J, Drobetsky E, Masson JY, Di Noia JM and Affarel B. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:285- 290.
41. Hummel R, Hussey DJ and Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. European journal of cancer. 2010; 46:298- 311.
42. Ma J, Dong C and Ji C. MicroRNA and drug resistance. Cancer gene therapy. 2010; 17:523-531.
43. Shiloh Y. ATM: expanding roles as a chief guardian of genome stability. Experimental cell research. 2014; 329:154-161.
44. Kothandapani A, Dangeti VS, Brown AR, Banze LA, Wang XH, Sobol RW and Patrick SM. Novel role of base excision repair in mediating cisplatin cytotoxicity. The Journal of biological chemistry. 2011; 286:14564-14574.
45. Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV and Croce CM. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Molecular oncology. 2012; 6:458- 472.
46. Krek W, Ewen ME, Shirodkar S, Arany Z, Kaelin WG, Jr. and Livingston DM. Negative regulation of the growthpromoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell. 1994; 78:161-172.
47. Palmieri D, D'Angelo D, Valentino T, De Martino I, Ferraro A, Wierinckx A, Fedele M, Trouillas J and Fusco A. Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene. 2012; 31:3857-3865.